Moderna (MRNA) stock is in focus as its updated mNEXSPIKE COVID vaccine boosts antibodies 15-fold on average against the new ...

Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE ...

Moderna said on Tuesday its updated COVID-19 vaccine formulation elicited a strong immune response in all adults aged 65 and ...

Discover why Moderna (MRNA) and MRNY ETF present high risks and limited upside for investors. Learn why avoiding both is the ...

Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in ...

Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groups Both of Moderna’s COVID-19 vaccines for the ...

Moderna said on Tuesday its updated COVID-19 vaccine formulation elicited a strong immune response in all adults aged 65 and ...

Moderna said on Tuesday its updated COVID-19 vaccine elicited a strong immune response in all adults age 65 and older, as ...

Moderna (MRNA) announced preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE, which targets the LP.8.1 variant of SARS-CoV-2 to ...

The updated formula for Moderna’s COVID-19 vaccine generates a 16-fold increase in antibodies neutralize the intended SARS-CoV-2 variant.

Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groupsBoth of Moderna's COVID-19 vaccines for the ...

Companies are moving from using AI for distinct operations to applying the technology for control and optimization of the ...